50 results about "Cough suppressants" patented technology

A mixed-release tablet or capsule formulation including vehicles for the delivery of a plurality of drugs in various combinations of immediate release, extended release, and/or delayed release modes over a predetermined time period have been developed, which provide for controlled release not just of the drugs, but controlled release that is designed to create more effective coordination between the drugs being delivered. The drugs can be any medically and/or physiologically appropriate combination of drugs and active ingredients, preferably decongestant drugs, antihistamines, expectorants, antitussives, cough suppressants, and drying agents.

A system and method for suppressing coughs, congestion and related symptoms is provided. The composition sprayed into the oral cavity may contain a cough suppressant and other ingredients such as decongestants, flavorings, sweeteners, stablizers, and/or preservatives. The composition is sprayed into the oral cavity utilizing a spray pattern having a spray pattern ratio from about 1.0 to about 1.19. The method of application comprises multiple applications of the composition every four to six hours according to condition severity and a user's age characteristics.

A cough suppressant garment may be worn around the neck of the user. The cough suppressant garment may have three layers, and one or more of the three layers may be manufactured from a woven material, such as, for example, cotton. An end of the cough suppressant garment may reversibly attach to an opposite end of the cough suppressant garment to maintain a position of the cough suppressant garment on the neck of the user.

Methods and compositions are disclosed utilizing metabolic derivatives of astemizole for the treatment of allergic disorders while avoiding the concomitant liability of adverse effects associated with the astemizole. The metabolic derivatives of astemizole are also useful for the treatment of retinopathy and other small vessel disorders associated with diabetes mellitus and such other conditions as may be related to the antihistamine activity of astemizole. For example, the metabolic derivatives of astemizole are useful for the treatment of asthma, motion sickness, and vertigo, without the concomitant liability of adverse effects associated with astemizole. Furthermore, the metabolic derivatives of astemizole, in combination with non-steroidal anti-inflammatory agents or other non-narcotic analgesics, or in combination with a decongestant, cough suppressant/antitussive or expectorant, are useful for the treatment of cough, cold, cold-like, and/or flu symptoms and the discomfort, headache, pain, fever, and general malaise associated therewith, without the concomitant liability of adverse effects associated with astemizole.

Methods and compositions are disclosed utilizing metabolic derivatives of astemizole for the treatment of allergic disorders while avoiding the concomitant liability of adverse effects associated with the astemizole. The metabolic derivatives of astemizole are also useful for the treatment of retinopathy and other small vessel disorders associated with diabetes mellitus and such other conditions as may be related to the antihistamine activity of astemizole. For example, the metabolic derivatives of astemizole are useful for the treatment of asthma, motion sickness, and vertigo, without the concomitant liability of adverse effects associated with astemizole. Furthermore, the metabolic derivatives of astemizole, in combination with non-steroidal anti-inflammatory agents or other non-narcotic analgesics, or in combination with a decongestant, cough suppressant/antitussive or expectorant, are useful for the treatment of cough, cold, cold-like, and/or flu symptoms and the discomfort, headache, pain, fever, and general malaise associated therewith, without the concomitant liability of adverse effects associated with astemizole.

A cough catching apparatus includes a body for securing to a hand of an individual, the body having an outer surface, an area on the outer surface having a material thereon, and a disinfectant infused into the material. The body may be a glove body. The glove body may have an opening for inserting a hand into the glove body and a plurality of finger openings. The area may be a palm area, a top of hand area, or may include both a palm area and a top of hand area.

A cough suppressor according to the present invention includes a chewable inner layer having a predetermined flavor. Preferably, the inner layer is chewing gum. The cough suppressor also includes an active layer situated outside the inner layer and that includes a cough suppressant. In addition, a buffer layer completely separates the inner layer from the active layer. The buffer layer includes a predetermined flavor and ensures that the active layer does not interfere with the flavor of the inner layer. According to another embodiment, a cough suppressant system includes the cough suppressor and one or more auxiliary flavor tablets, each of which includes a desirable flavor such that this flavor may be selectively maintained long after the flavor of the inner layer is consumed. A cough suppressant liquid may be included for application to the flavor tablets.

A device for adding a flavor and/or cough suppressant component to an inhaler is described. The device includes a housing having an interior chamber, wherein the housing includes at least one air inlet and at least one air outlet connected to the interior chamber, thereby forming an airflow pathway through the interior chamber, and at least one flavoring and/or cough suppressant component positioned within the interior chamber, wherein the housing is attachable to an exterior surface of an inhaler having at least one air inlet, such that the at least one air outlet of the device aligns with the at least one air inlet of the inhaler to form an airflow path through the device and into the inhaler.

The invention discloses an online sweeping-micellar electrokinetic chromatography method for separating and measuring protocatechuic acid in acute bronchitis syrup. In micelle capillary electrophoresis, the electrophoresis conditions are that the buffer system refers to 20mmol/L sodium dihydrogen phosphate, 80mmol/L SDS and 12.5 percent (V/V) of acetonitrile with the pH value of 2.2; the detection wavelength is 225nm; the ambient temperature is 25 DEG C. The online sweeping-micellar electrokinetic chromatography method comprises the following steps: diluting a to-be-detected standard substance and sample solution to a proper concentration by using water, wherein the separation voltage is -20kV; and performing gravity injection, wherein the injection height is 16cm, and the injection time is 60 seconds; and the detection limit of protocatechuic acid is 15.96mu g/L. The method disclosed by the invention has the beneficial effects that the online sweeping-micellar electrokinetic chromatography method has good enrichment effect and detection limit, and the method is simple, rapid, high in sensitivity and high in reproducibility and can be used for separating protocatechuic acid and measuring content of protocatechuic acid in cough medicines.

The invention discloses an online sweeping-micellar electrokinetic chromatography method for separating and measuring ferulic acid in acute bronchitis syrup. In micelle capillary electrophoresis, the electrophoresis conditions are that the buffer system refers to 20mmol/L sodium dihydrogen phosphate, 80mmol/L SDS, and 12.5 percent of acetonitrile with the pH value of 2.2; the detection wavelength is 225nm; the ambient temperature is 25 DEG C. The online sweeping-micellar electrokinetic chromatography method comprises the following steps: diluting a to-be-detected standard substance and sample solution into a proper concentration by using water, wherein the separation voltage is -20kV; and performing gravity injection, wherein the injection height is 16cm, and the injection time is 60 seconds; and the detection limit of ferulic acid is 109.95mu g/L. The method disclosed by the invention has the beneficial effects that the online sweeping-micellar electrokinetic chromatography method has good enrichment effect and detection limit, and the method is simple, rapid, high in sensitivity and high in reproducibility and can be used for separating ferulic acid and measuring content of ferulic acid in cough medicines.

The invention relates to a pharmaceutical composition for preventing phlegm from forming and stopping coughing. In particular to application of glycyl prolyl serine to preparation of a medicine for preventing phlegm from forming and stopping cough, a medicine composition containing glycyl prolyl serine and used for preventing phlegm from forming and stopping cough and a preparation method of the medicine composition. The phlegm reducing and cough stopping effects of glycyl prolyl serine are found for the first time, the glycyl prolyl serine is further prepared into the oral preparation, and it is proved through a mouse toxicity test, a mouse cough model, a guinea pig cough model, a mouse expectoration test model and a beagle cough phlegm test model that after the glycyl prolyl serine is prepared into the oral pharmaceutical composition, the effect of reducing phlegm and stopping cough is achieved. The obvious effects of reducing phlegm and stopping coughing are achieved.

The invention discloses an anti-inflammation cough suppressant. The anti-inflammation cough suppressant is characterized by being prepared from, by weight, 13 g of herba ephedrae, 12 g of all-grass offascicleleaf rockfoil, 11 g of bitter apricot seeds, 5 g of rhizoma pinelliae, 11 g of radix ophiopogonis, 10 g of radix asteris, 9 g of radix stemonae, 9 g of fructus lycii and 6 g of radix glycyrrhizae. The medicine efficacies of the raw medicine materials selected by the anti-inflammation cough suppressant are complementary, mutual inhibition, mutual restraint and mutual detoxication of the compatibility between the medicines are avoided, the effects of mutual promotion and mutual assistance of the medicines are significant, and the anti-inflammation cough suppressant has the functions ofrelieving interior syndromes and relieving a cough. When the anti-inflammation cough suppressant is taken orally, chronic cough is treated, and the anti-inflammation cough suppressant has a definite effect.